[Market Focus] Aliglo Gains Traction in U.S. Market... GC Up 3.57%

With Aliglo, GC's core treatment for congenital immunodeficiency, performing well in the United States, the company's stock price is also on the rise.

As of 9:18 a.m. on September 19, GC was trading at 136,500 won, up 4,700 won (3.57%) from the previous trading day.

On this day, IBK Investment & Securities stated, "Expectations for achieving mid- to long-term goals will rise further as Aliglo establishes itself in the U.S. market," maintaining a buy rating and setting a target price of 190,000 won for GC.

Jung Isu, a researcher at IBK Investment & Securities, said, "Aliglo is expected to achieve its initial annual sales target of 100 million dollars in the U.S. market this year. Since its launch in August last year, cumulative sales have surpassed 100 billion won within one year, and quarterly sales continue to increase. If the sales target is achieved, the operating margin will reach 20%, contributing to profit growth this year."

This content was produced with the assistance of AI translation services.